Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EPS (Basic) (2016 - 2025)

Abeona Therapeutics has reported EPS (Basic) over the past 15 years, most recently at -$0.42 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.42 for Q4 2025, down 200.0% from a year ago — trailing twelve months through Dec 2025 was $1.31 (up 175.29% YoY), and the annual figure for FY2025 was $1.34, up 186.45%.
  • EPS (Basic) for Q4 2025 was -$0.42 at Abeona Therapeutics, down from -$0.1 in the prior quarter.
  • Over the last five years, EPS (Basic) for ABEO hit a ceiling of $2.07 in Q2 2025 and a floor of -$11.64 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.51 (2023), compared with a mean of -$1.17.
  • Biggest five-year swings in EPS (Basic): crashed 6747.06% in 2021 and later skyrocketed 989.47% in 2025.
  • Abeona Therapeutics' EPS (Basic) stood at -$11.64 in 2021, then soared by 104.47% to $0.52 in 2022, then tumbled by 223.08% to -$0.64 in 2023, then soared by 78.12% to -$0.14 in 2024, then plummeted by 200.0% to -$0.42 in 2025.
  • The last three reported values for EPS (Basic) were -$0.42 (Q4 2025), -$0.1 (Q3 2025), and $2.07 (Q2 2025) per Business Quant data.